Rapamycin, also known as sirolimus, is a naturally derived macrolide originally isolated from soil collected on Rapa Nui. It inhibits the mTOR signaling pathway and has established immunosuppressive medical uses. The page reviews immune-aging and longevity research, distinguishing laboratory-organism findings from inconclusive evidence for lifespan extension in healthy humans.
What Is Rapamycin (Sirolimus)?
Rapamycin is a naturally derived macrolide originally isolated from soil collected on Easter Island, or Rapa Nui. It was initially characterized for antifungal activity, but subsequent research established that its most important biological effects involve inhibition of the mammalian or mechanistic target of rapamycin pathway. Sirolimus is the approved pharmaceutical name for rapamycin and is used clinically as an immunosuppressant in selected transplantation settings and in certain vascular and oncologic applications. The compound is available in oral formulations, and its pharmacology is influenced by absorption, hepatic metabolism, drug interactions, and substantial interindividual variation in blood concentrations.
In longevity research, rapamycin is studied because mTOR signaling integrates amino acids, insulin, growth factors, cellular energy, and stress signals. Persistent nutrient and growth signaling can promote protein synthesis and cellular growth while suppressing autophagy, whereas partial or intermittent pathway inhibition may activate cellular maintenance programs. Lifespan extension has been demonstrated in several laboratory organisms, most prominently in genetically heterogeneous mice. However, evidence that rapamycin extends healthy lifespan in otherwise healthy humans is not yet conclusive, and anti-aging use should be regarded as experimental rather than established medical care.
Quick Reference
Member reference tables summarize the compound's research parameters.
Sirolimus binds FKBP12 to form a complex that selectively inhibits mTOR complex 1, reducing nutrient-responsive anabolic signaling and protein synthesis.
Autophagy-related signaling
mTORC1 suppression is a well-established upstream signal for autophagy initiation in cell and animal research models.
Longevity Research
Strong Evidence
Lifespan extension in model organisms
Rapamycin extends lifespan in yeast, flies, worms, and genetically heterogeneous mice; these findings do not establish a human longevity indication.
Late-life intervention studies
Mouse studies report lifespan benefits even when treatment begins in midlife or later, supporting continued investigation of timing and dosing schedules.
Immune Aging Studies
Supported Research
Responses to influenza vaccination
Low-dose mTOR inhibition has been studied in older adults for effects on immune function and influenza vaccine response, with regimen-dependent findings.
Infection-risk tradeoff
At conventional immunosuppressive exposure, sirolimus can increase susceptibility to infection; low-dose geroscience findings cannot be generalized to all populations.
Age-Related Healthspan
Emerging Evidence
Metabolic and tissue outcomes
Preclinical studies examine effects on age-associated functional decline, but human healthspan outcomes remain unproven.
Intermittent dosing hypotheses
Intermittent schedules are being explored to balance mTORC1 modulation with adverse-effect burden; optimal human schedules are unknown.
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below), not a personal dosing recommendation.
This member section describes parameters reported in the research literature.
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
This member section discusses research safety considerations and uncertainties.
Prefer prescription product dispensed by a licensed pharmacy with traceable manufacturer, lot number, expiration date, and intact packaging.
Verified Marker
Strength and dosage-form labeling
The label should clearly state sirolimus strength in milligrams, tablet or oral-solution form, lot identifier, storage instructions, and expiry date.
Verified Marker
Manufacturer quality documentation
For compounded preparations, request a certificate of analysis covering identity, potency, microbial limits, and heavy-metal testing where applicable.
Acceptable Range
Independent analytical testing
If third-party testing is presented, it should be lot-specific and use an appropriate method such as HPLC for identity and potency rather than a generic certificate.
Quality Concern
Unverified research or supplement sources
The listed research text specifies avoiding products without pharmacy provenance, reliable lot traceability, stated milligram accuracy, or authentic batch-specific testing documentation.